Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cherry fruit tame metabolic syndrome?

NCT ID NCT07739602

Disease control Sponsor: Wroclaw Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This trial tests whether taking a daily supplement of cornelian cherry fruit for six months can improve markers of heart, blood vessel, eye, and bone health in people with metabolic syndrome. Participants will receive either the cherry supplement or a placebo, and researchers will measure a wide range of health indicators, including blood pressure, cholesterol, blood sugar, and eye blood flow. The goal is to see if this natural fruit could offer a simple way to reduce the risks associated with metabolic syndrome.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cornelian cherry fruit lyophilizate (Cornus mas L.)
What this could lead to
If effective, this natural supplement could offer a simple way to support heart, eye, and bone health in people with metabolic syndrome.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. The supplement may not produce significant benefits, and any effects could be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jan 2019

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 70 years * Metabolic syndrome defined as central obesity, with a waist circumference of ≥94 cm in men or ≥80 cm in women, and at least two of the following: * Fasting triglyceride concentration ≥1.7 mmol/L * Low high-density lipoprotein cholesterol concentration: \<1.03 mmol/L in men or \<1.29 mmol/L in women * Elevated blood pressure: systolic blood pressure ≥130 mmHg and diastolic blood pressure ≥85 mmHg * Fasting glucose concentration ≥6.5 mmol/L * Best-corrected visual acuity of 20/40 or better * Spherical refractive error between -4.0 and +4.0 diopters * Cylindrical refractive error between -3.0 and +3.0 diopters Exclusion Criteria: * Current smoking * Insulin-dependent diabetes mellitus * Liver disease * Gastrointestinal disease * Cancer * Inflammatory disease * Use of weight-loss medication * Use of anti-inflammatory medication * Pregnancy * Breastfeeding * Alcohol or drug abuse * Requirement to follow a medically prescribed diet other than the diet recommended for metabolic syndrome * Hypotension * Severe circulatory failure * Vascular endothelial abnormalities that could affect blood flow to the optic nerve head * Ocular surgery within 12 months before enrollment * Age-related macular degeneration * Diabetic retinopathy * Retinal vein occlusion * Glaucoma * Other serious acquired or hereditary ocular disease * Neurological disorder that could interfere with ophthalmological examinations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome

Contacts and locations

Locations

  • Department of Pharmacology, Wroclaw Medical University

    Wroclaw, 50-345, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.